SHANG.FOS.PHARM.GR.H YC 1 (F:08HH) — Stock Price
SHANG.FOS.PHARM.GR.H YC 1 (F:08HH) is currently trading at €1.86 EUR, up 0.11% today. Over the past 52 weeks, shares have ranged between €1.66 and €3.22. This page tracks SHANG.FOS.PHARM.GR.H YC 1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 08HH stock market capitalisation.
SHANG.FOS.PHARM.GR.H YC 1 (08HH) Stock Price Chart — Daily History & Trading Volume
The chart below tracks SHANG.FOS.PHARM.GR.H YC 1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
SHANG.FOS.PHARM.GR.H YC 1 Income Statement — Revenue, Profit & Earnings by Year
SHANG.FOS.PHARM.GR.H YC 1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €41.66 Billion | €41.07 Billion | €41.40 Billion | €43.95 Billion | €39.01 Billion |
| Cost of Revenue | €20.80 Billion | €21.37 Billion | €21.60 Billion | €23.17 Billion | €20.23 Billion |
| Gross Profit | €20.86 Billion | €19.70 Billion | €19.80 Billion | €20.78 Billion | €18.78 Billion |
| Research & Development | €4.01 Billion | €3.64 Billion | €4.35 Billion | €4.30 Billion | €3.84 Billion |
| SG&A | €6.80 Billion | €6.47 Billion | €7.37 Billion | €7.10 Billion | €7.41 Billion |
| Total Operating Expenses | €38.52 Billion | €37.86 Billion | €39.84 Billion | €40.31 Billion | €36.30 Billion |
| Operating Income | €3.15 Billion | €3.20 Billion | €1.56 Billion | €3.64 Billion | €2.71 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €1.27 Billion | €1.43 Billion | €1.32 Billion | €963.81 Million | €822.53 Million |
| Income Before Tax | €5.11 Billion | €4.17 Billion | €3.26 Billion | €4.57 Billion | €6.04 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €3.37 Billion | €2.77 Billion | €2.39 Billion | €3.73 Billion | €4.73 Billion |
SHANG.FOS.PHARM.GR.H YC 1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes SHANG.FOS.PHARM.GR.H YC 1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €120.05 Billion | €117.46 Billion | €113.47 Billion | €107.16 Billion | €93.31 Billion |
| Total Current Assets | €33.82 Billion | €34.49 Billion | €33.79 Billion | €35.28 Billion | €30.44 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €2.25 Billion | €2.60 Billion | €1.89 Billion | €928.53 Million | €4.24 Billion |
| Net Receivables | €9.36 Billion | €7.95 Billion | €7.64 Billion | €7.59 Billion | €6.03 Billion |
| Inventory | €6.25 Billion | €7.26 Billion | €7.54 Billion | €6.88 Billion | €5.47 Billion |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €10.81 Billion | €10.91 Billion | €10.85 Billion | €10.34 Billion | €9.40 Billion |
| Total Liabilities | €58.21 Billion | €57.53 Billion | €56.85 Billion | €53.05 Billion | €44.93 Billion |
| Total Current Liabilities | €36.42 Billion | €37.45 Billion | €33.76 Billion | €33.30 Billion | €29.32 Billion |
| Long-term Debt | €11.86 Billion | €10.44 Billion | €13.50 Billion | €12.10 Billion | €9.05 Billion |
| Net Debt | €14.29 Billion | €15.63 Billion | €14.54 Billion | €7.79 Billion | €8.15 Billion |
| Total Stockholder Equity | €48.74 Billion | €47.26 Billion | €45.68 Billion | €44.58 Billion | €39.20 Billion |
| Retained Earnings | €29.06 Billion | €26.55 Billion | €24.54 Billion | €23.22 Billion | €21.03 Billion |
SHANG.FOS.PHARM.GR.H YC 1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how SHANG.FOS.PHARM.GR.H YC 1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €5.21 Billion | €4.48 Billion | €3.41 Billion | €4.22 Billion | €3.94 Billion |
| Capital Expenditures | €4.45 Billion | €4.41 Billion | €5.34 Billion | €5.89 Billion | €4.97 Billion |
| Free Cash Flow | €764.78 Million | €66.79 Million | €-1.92 Billion | €-1.67 Billion | €-1.03 Billion |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | €-1.94 Billion | €2.06 Billion | €2.46 Billion | €2.37 Billion | €1.91 Billion |
| Stock-Based Compensation | €207.24 Million | €21.07 Million | €35.90 Million | €54.48 Million | €64.29 Million |
| Depreciation | €3.51 Billion | €3.00 Billion | €2.97 Billion | €2.34 Billion | €1.83 Billion |
| Change in Cash | €-353.44 Million | €-110.94 Million | €-1.67 Billion | €4.71 Billion | €-873.79 Million |
SHANG.FOS.PHARM.GR.H YC 1 Earnings History — EPS Actual vs. Analyst Estimates
Track SHANG.FOS.PHARM.GR.H YC 1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 24, 2026 | — | — | — |
| Apr 27, 2026 | — | — | — |
| Mar 24, 2026 | — | — | — |
| Oct 29, 2025 | — | — | — |
| Aug 26, 2025 | — | — | — |
| Mar 24, 2025 | — | — | — |
| Oct 29, 2024 | — | — | — |